Endobronchial valve
An endobronchial valve is an implantable medical device--a small, one-way valve, which is implanted in an airway in the pulmonary system to treat one of several lung conditions. The one-way endobronchial valve is typically implanted such that when a patient exhales, air is able to flow through the valve and out of the lung compartment that is fed by that airway, but when the patient inhales, the valve closes and blocks air from entering that lung compartment. Thus, an implanted endobronchial valve typically helps a lung compartment to empty itself of air. This has been shown to be beneficial in the treatment of emphysema, where lungs lose their elasticity and thus cannot contract sufficiently to exhale air, leading to air trapping and hyperaeration. When one or more diseased portions of an emphysematous lung are made to deflate and collapse, other healthier portions of the lung have more room in the chest cavity to inhale and exhale, pressure is removed from the diaphragm, and even the heart may function better as the hyperinflated lung becomes smaller.[1] Endobronchial valves have also been shown to be beneficial in treatment of persistent air leaks in the lungs. It has also been theorized that endobronchial valves may be useful for treatment of tuberculosis and its complications.
Endobronchial valves were developed primarily by the start-up medical device company Emphasys Medical (now Pulmonx - Redwood City, California) as a minimally invasive alternative to lung volume reduction surgery for emphysema. In lung volume reduction surgery, a surgeon cuts into a patient's chest and cuts out one or more most diseased portion(s) of a lung. Endobronchial valves were designed to replicate the effects of that procedure without requiring incisions, by simply allowing the most diseased portions of the lung to collapse. Emphasys was purchased by Pulmonx in 2009, and Pulmonx currently markets the Zephyr® endobronchial valve (developed by Emphasys) in Europe, Australia, China and many other locations outside the U.S. Pulmonx also sells the Chartis® Pulmonary Assessment System, which is a patient assessment tool used with endobronchial valves to help physicians target appropriate lung compartments for treatment. Another company, Spiration (Seattle, Washington), developed a different type of endobronchial valve and was acquired by Olympus in 2010.
Endobronchial valves may be the first successful medical device treatment of emphysema, a disease that affects billions of patients worldwide and has no known cure. Endobronchial valves are typically implanted using a flexible delivery catheter advanced through a bronchoscope, and thus they are very minimally invasive. The valves are also removable if they are not working properly. When properly used and correctly implanted, endobronchial valves have been shown to improve patients' ability to breathe, walk, exercise and perform their daily activities. Although not yet approved by the Food and Drug Administration for emphysema treatment in the United States, endobronchial valves are available in many other locations throughout the world and should be available in the U.S. eventually.
References
- ↑ Script error
External links
